PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study.
Zhi-Ming WuJing KanFei YeWei YouXiang-Qi WuNai-Liang TianSong LinZhen GeZhi-Zhong LiuXiao-Bo LiXiao-Fei GaoJing ChenYan WangShang-Yu WenPing XieHong-Liang CongLi-Jun LiuHe-Song ZengLei ZhouFan LiuYong-Hong ZhengRui LiHong-Lei JiSheng-Hua ZhouShou-Ming ZhaoXue-Song QianJun LuoXin WangJun-Jie ZhangShao-Liang ChenPublished in: American heart journal (2024)
The SHAWN study has been specifically designed to evaluate the effectiveness and safety of adding a PCSK9 inhibitor to high-intensity statin therapy in patients who have experienced ACS following PCI. The primary objective of this study is to generate new evidence regarding the potential benefits of combining a PCSK9 inhibitor with high-intensity statin treatment in reducing cardiovascular events among these patients.
Keyphrases
- high intensity
- cardiovascular events
- coronary artery disease
- percutaneous coronary intervention
- cardiovascular disease
- resistance training
- double blind
- acute coronary syndrome
- acute myocardial infarction
- heart failure
- atrial fibrillation
- end stage renal disease
- coronary artery bypass grafting
- st elevation myocardial infarction
- study protocol
- type diabetes
- st segment elevation myocardial infarction
- radiation therapy
- antiplatelet therapy
- prognostic factors
- bone marrow
- replacement therapy
- body composition
- human health
- phase iii
- rectal cancer